PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Positive data for Acesion’s atrial fibrillation candidates

The company intends to advance AF drugs that address current risk concerns with existing therapies.

Acesion Pharma – a company focusing on atrial fibrillation (AF) therapies – has announced positive data from pre-clinical studies of its AP31969 treatment.

The candidate is a second-generation oral SK channel inhibitor specifically developed to prevent AF recurrence.

Ultimately, Acesion intends to advance AF drugs that address the primary concern with existing therapies – the high risk of life-threatening cardiac arrhythmia, also known as proarrhythmia.

In order to determine proarrhythmia risk in respect of the drug, regulators, academics and the wider industry have collaborated on developing pre-clinical models with this purpose in mind. Among two of the other models, AP31969 has established a low risk of proarrhythmia with a clear distinction between other AF drugs, which have previously shown a high risk of the side effect.

Furthermore, the candidate’s promising cardiac safety profile has demonstrated good oral pharmacokinetic properties across various animal species.

Meanwhile, AP30663, Acesion’s SK ion channel inhibitor for conversion of AF to normal sinus rhythm, has also demonstrated significant efficacy in patients with AF. Another candidate, AP31969 has completed toxicology studies required by regulatory authorities, in anticipation of a phase 1 trial which Acesion plans to commence later in 2023.

Anders Gaarsdal Holst, chief executive officer of Acesion, was confident that the results could make a long-term difference to the lives of patients with AF: “With a growing number of patients suffering from AF, there is a significant need for treatment. Unfortunately, all existing drugs have major safety issues that endanger patients.”

He added: “Acesion’s positive pre-clinical results support that AP31969 has the potential to solve these issues and greatly broaden the use of pharmacological treatment within AF. We are excited to continue the development of AP31969 with a phase 1 clinical trial and look forward to the continued progress we will make in the coming year.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026